Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

16

Revenue 2017

Tecfidera

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tecfidera was produced by Biogen Idec.

2015 set to be a transitional year for Merck KGaA's health unit

2015 set to be a transitional year for Merck KGaA's health unit Rebif sales fell nearly 16% to 430m as the MS market continues to switch towards oral therapies such as Biogen Idec's Tecfidera (dimethyl glutamate) and Novartis' Gilenya (fingolimod).

Pfizer maintains lead in top CNS drug sales - just

Pfizer maintains lead in top CNS drug sales - just new agents in the form of Tecfidera(dimethyl fumarate) and Plegridy(peginterferon beta-1a).  .

Biogen Idec plans phase III Alzheimer's trial before year-end

Biogen Idec plans phase III Alzheimer's trial before year-end out of oral therapy Tecfidera (dimethyl fumarate) overseas hid a slowdown in the US market. ... Overall, Tecfidera posted sales of $916m in the quarter, up from a little under $400m a year ago, which helped Biogen Idec's overall revenues grow by 34% to $2

Biogen Idec enlists son of NFL star for MS campaign

Biogen Idec enlists son of NFL star for MS campaign Biogen Idec has long been in leader in MS therapies, with major products including Tysabri (natalizumab) and the oral medicine Tecfidera (dimethyl fumarate).

Novartis’ Gilenya fails in difficult-to-treat form of MS

Novartis’ Gilenya fails in difficult-to-treat form of MS hit market, including Sanofi's Aubagio (teriflunomide) and Biogen Idec's Tecfidera (dimethyl fumarate).

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics